Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108 combined with furmonertinib with or without toripalimab in MET-positive EGFR-mutant NSCLC after EGFR-TKI failure
CTR20231178Phase 2Active
- Sponsor
- RemeGen
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RC108, furmonertinib, toripalimab in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Started Sep 2023; status: active.
02
Drugs
RC108furmonertinibtoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20231178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231178.